» Articles » PMID: 33774631

Fertility of Women Treated During Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study

Overview
Publisher Karger
Date 2021 Mar 28
PMID 33774631
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gonadotropin-releasing hormone analogues (GnRHa) administered as depot formulations are the standard of care for children with central precocious puberty (CPP). Puberty resumes after treatment discontinuation, but little is known concerning fertility in women who have been treated with GnRHa for CPP during childhood.

Methods: The PREFER (PREcocious puberty, FERtility) study prospectively analysed fertility, via a series of questionnaires, in women treated during childhood with triptorelin (depot formulation) for CPP. Co-primary endpoints were the proportion of women wanting a pregnancy any time before study inclusion and during the follow-up period but not pregnant 6 and 12 months after stopping contraception and the waiting time to pregnancy (WTP).

Results: A total of 574 women were identified, and 194 women were included in the analysis. Although there were not enough data for primary endpoint assessment, few women (1.7%) reported issues with fertility or were unable to become pregnant despite trying to conceive. Most pregnancies (84.4%, 95% CI [67.2-94.7%]) occurred within 1 year of trying to conceive, in line with the WTP for women without previous CPP.

Conclusion: The results, based on a limited sample of patients, suggest that CPP treated with triptorelin does not negatively impact women's fertility in adulthood. These results need to be consolidated with a subsequent study performed when these women will have reached their mid-thirties.

Citing Articles

Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update.

Soliman A, Alaaraj N, De Sanctis V, Hamed N, Alyafei F, Ahmed S Acta Biomed. 2023; 94(6):e2023222.

PMID: 38054666 PMC: 10734238. DOI: 10.23750/abm.v94i6.15316.


2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents.

Kim S, Kim J, Hong Y, Chung I, Lee E, Kang E Ann Pediatr Endocrinol Metab. 2023; 28(3):168-177.

PMID: 37798893 PMC: 10556443. DOI: 10.6065/apem.2346168.084.


Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States.

Popovic J, Geffner M, Rogol A, Silverman L, Kaplowitz P, Mauras N Front Pediatr. 2022; 10:968485.

PMID: 36268040 PMC: 9577333. DOI: 10.3389/fped.2022.968485.


Reproductive health risks and clinician practices with gender diverse adolescents and young adults.

Quinn G, Tishelman A, Chen D, Nahata L Andrology. 2021; 9(6):1689-1697.

PMID: 33942552 PMC: 8566321. DOI: 10.1111/andr.13026.

References
1.
Boivin J, Bunting L, Collins J, Nygren K . International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007; 22(6):1506-12. DOI: 10.1093/humrep/dem046. View

2.
Guaraldi F, Beccuti G, Gori D, Ghizzoni L . MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2015; 174(3):R79-87. DOI: 10.1530/EJE-15-0590. View

3.
Martinez-Aguayo A, Hernandez M, Beas F, Iniguez G, Avila A, Sovino H . Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006; 19(8):963-70. DOI: 10.1515/jpem.2006.19.8.963. View

4.
Prioux F, Barbieri M . Recent Demographic Developments in France: Relatively Low Mortality at Advanced Ages. Population (Engl Ed). 2013; 67(4). PMC: 3839870. DOI: 10.3917/pope.1204.0493. View

5.
Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G . Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod. 2003; 18(9):1959-66. DOI: 10.1093/humrep/deg366. View